
There are more than 80 types of human papillomavirus (HPV) and approximately 30 strains are associated with genital infection. Several of the strains can be associated with cervical neoplasia. Evidence is accumulating to show that detection of persistent HPV infection could help detect those at most risk of cervical neoplasm disease progression.

This study looked at the diversity of HPV infection and its association with cervical neoplasia. It used 3444 randomly selected samples, which were residual from liquid-based cytology samples. Its aim was to investigate the overall prevalence of HPV, the type specific prevalence and the number with multiple infections. This was then compared with the cytological assessment for neoplasia.

Approximately 10% of the samples showed some detectable HPV and 16.3% of samples detected 20% of samples, and 77% of these showed a high-risk type of HPV. Surprisingly, 42% of the positive samples from under-25-year-olds were identified.

The results also showed that with increasing severity of dyskaryosis on cervical sample there was an increasing prevalence of HPV virus. Infection with multiple HPV types were found in 3.4% of negative sample and in 33.3%, 41.8% and 40.4% of samples with borderline, mild or high-grade dyskaryosis, respectively. HPV infection with a single type showed a similar picture. Type-specific detection of HPV in multiple infections is in progress and this may influence the addition of HPV testing to the cervical screening programme. The result of current pilot studies looking for HPV in under-25-year-olds may also help with this decision.

Reviewed by Laura Patterson, MRCGP, MFFP
GP Non-specialist, Associate Specialist in Family Planning, Swindon, UK


This paper analyses the cost-effectiveness of a contraceptive for women who use the USA in relation to the prevention of pregnancy and cost saving of a method. It does not include all methods, for example, implants, and excludes vasectomy costs.

The probability of a woman discontinuing a method or complications requiring medical treatment was estimated from USA national data and surveys. The model used some assumptions; including how a woman uses contraception. The study only included parous women, and it assumed that if a patient discontinued a method she would start another. It was assumed that if a woman giving birth a woman would start a method within 2 months and that, when calculating the cost for barrier methods, it was assumed that a woman had 83 acts of sexual intercourse a year.

The conclusions drawn from the calculations were that intrauterine devises or the intrauterine system are the most cost-effective methods to use. The way in which the calculations were carried out was well illustrated and could easily be adapted for the UK. It would be interesting to see if by including implant and vasectomy for the UK figures a subsequent study would come out with a different conclusion.

It has to be remembered that this is purely a hypothetical calculation as we all know women who fall outside the standard criteria as described above. Until the variables set by all contraceptive users are fully addressed it is likely that any calculations can only give a rough estimate of the cost-effectiveness of a particular method.

Reviewed by Judy Murty, DRCOG, MFFP
SCMO, Contraception and Sexual Health Services, Leeds, UK


This is another report derived from the data acquired from the Family Planning Health Association (IpA) Study. Readers will remember that the study recruited around 17,000 married women between the ages of 25 and 39 years, from 17 family planning clinics between 1968 and 1974, who used oral contraceptives (OCs), a diaphragm or an intrauterine device. By the end of December 2000, 889 women had died.

The study found no overall increased risk of death from all causes among women who used OCs (regardless of duration of pill use) compared with women in the study who had never used OCs. Although the data suggested that the overall risk of death in OC users was lower than among non-users, this did not quite reach statistical significance.

In comparison with non-smokers, light smokers showed a slightly increased death rate from causes of around 25%, and heavy smokers (women who smoked more than 15 cigarettes a day) showed more than a doubling of death risk from all causes. Even in women who smoked less than 15 cigarettes a day, the harmful effects of smoking were already apparent.

The study provided no surprises in reporting that in users of OCs compared with non-users, there was a decrease in mortality from uterine and ovarian cancer and from breast cancer but an increase in cervical cancer and smoking-related mortality. The numbers are all small with wide confidence intervals. Although women who took OCs and did not smoke, or only smoked lightly, showed no increased mortality from ischaemic heart disease, women who took OCs and smoked heavily showed a slightly increased death rate. The study did not show any relationship between length of OC use and smoking-related mortality, nor between smoking and breast cancer mortality. These figures need to be considered together with the knowledge that this study did not recruit young women starting OCs before the full term of pregnancy and that only 16% of the total number of women who died had recent or current exposure to OCs. A large number of other causes of death were examined in relation to smoking or taking OC use. This is useful information if you need to discuss specific risks with an individual woman.

The Oxford IpA Study is one of only three large-scale studies of long-term OC safety. It provides valuable data on the long-term effects of contraceptive use as well as morbidity and mortality among women of childbearing age. It does have some limitations. Long-term studies are subject to follow-up errors and numbers dwindle. The numbers of deaths from any cause in this age group is (thankfully) small. Most of the OCs used in the 1970s and early 1980s contained stilbestrol. It is unclear whether the findings can be extrapolated to the pills in use currently. Also, some effects of OCs (e.g. on cardiovascular disease or breast cancer) have been shown to apply mainly to current or very recent users. OCs are generally stopped when serious illness occurs, but death may not occur for many years. The analysis of the effects of smoking only considered the amount recorded at recruitment, and so the 12% of light smokers and 14% were heavy smokers.

The headlines in the news should have been: ‘Oral contraceptive use not harmful’. But, as usual, good news is no news. What we did not see either was the bad news: ‘Young women are killed by smoking’. This is an important study reporting the harmful effects of smoking on the health of young and middle-aged women. All women are urged to stop smoking with healthy individuals who might otherwise not see a health professional. Our primary task is to help them with their contraceptive needs, but we also have a responsibility to tell them about activities damaging to their future health.

Reviewed by Gill Wakley, MD, MFFP
Visiting Professor in Primary Care Development, Staffordshire University and Freelance GP and Writer. Abergavenny, UK


This paper is the fourth in recent years that has suggested that hormonal emergency contraception (EC) can be used on the fourth or fifth day after unprotected sexual intercourse (UPS1). This paper cites an imaginary woman who reported 4 days after UPS1. The author recommends that the regimen of progestogen (POC) be prescribed. This is justified by reference to clinical studies, in which hormonal EC on the fourth and fifth days appeared to be effective. It will be relevant to the various groups of the other three papers. The first paper described POEC given to 131 women between 72 hours after UPS1 compared to POEC given to 169 women between 72 and 120 hours after UPS1. The pregnancy rates were respectively 0.8% and 1.8%. The authors concluded that POEC could be given up to 120 hours after UPS1. The second paper was the World Health Organization (WHO) study presenting a review of 14 studies comparing UPS1 and UPS5. The pregnancy rates on Days 4 and 5 after UPS1 were 1.1% and 4.8%, respectively. The mifepristone rates on Days 4 and 5, respectively, were 1.0% and 5.3%.

The authors warn that “the small numbers of women given delayed treatments in this trial makes our estimation very imprecise”. The third paper compared 675 women who had used Yuzpe regime EC within 72 hours with 111 who had Yuze regime EC between 72 and 120 hours after UPS1. The uses were put into two groups: perfect users and typical users. The pregnancy rates were 1.5% and 5.3%, respectively. The 120 hour groups were, respectively, 1.9% and 3.6%.

The authors concluded that the Yuzpe regime EC could be given up to 120 hours after UPS1 effectively, and that perhaps evidence is building in favour of extending the 72-hour limit. Although numbers are limited it is interesting that the highest pregnancy rates in the WHO study did not occur till the fifth day with low rates of use from days 1 to 4 suggesting that the best limit may turn out to be 96 hours. Meanwhile, the official Faculty of Family Planning and Reproductive Health Care advice is that the limit should be 72 hours.3

References
1 Blease L, Graff D, Joly J. Effectiveness of emergency contraceptive pills between 72 hours and 120 hours after unprotected sexual intercourse. Am J Obstet Gynecol 2001; 184: 531–537.
6 Reviewd by Michael Cox, FRCOG, MFFP
Consultant Obstetrician and Gynaecologist (Retired), Nuneaton, UK